Biogen yanks its Aduhelm application in Canada, days after celebrating the drug's 1-year anniversary in the US
Add Canada to the list of countries where Biogen’s controversial Alzheimer’s drug Aduhelm isn’t wanted by health officials.
The biotech announced on Thursday that it’s pulling aducanumab’s new drug submission (NDS) in Canada after the country’s health agency indicated that “the data provided would not be sufficient to support a marketing authorization.”
The news comes just a couple of months after Biogen pulled aducanumab’s application in Europe, where regulators rejected it late last year — and almost a year to the date since the drug won its highly disputed accelerated approval in the US.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.